<DOC>
	<DOCNO>NCT02140840</DOCNO>
	<brief_summary>The purpose study evaluate overall response rate Trametinib administer orally patient relapse refractory multiple myeloma</brief_summary>
	<brief_title>UARK 2014-08 A Phase II Open-Label , Multiple-Dose , Single Agent Study Evaluate Overall Response Rate Orally Administered Trametinib</brief_title>
	<detailed_description>The effect tumor response determine use International Myeloma Working Group uniform response criterion analyze change serum urine value monoclonal protein immunoglobulin kappa lambda free light chain ratio , microglobulin , lactate dehydrogenase , hemoglobin C-reactive proten .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<criteria>Been identify multiple myeloma activate NRAS , KRAS BRAF genetic mutation CD138+ cell , identify molecular genetic testing Have diagnose multiple myeloma meet three follow IMWG criterion : Clonal bone marrow plasma cell &gt; 10 % b Presence serum and/or urinary Mprotein ( If monoclonal protein detect ( nonsecretory disease ) , &gt; /= 30 % monoclonal bone marrow plasma cell and/or biopsyproven plasmacytoma require . ) c Evidence endorgan damage attribute underlying plasma cell proliferative disorder , specifically , one following : ( ) Hypercalcemia : serum calcium &gt; 11.5 mg/100 mL ( ii ) Renal insufficiency : serum creatinine &gt; 2 mg/dL ( iii ) Anemia : normochromic , normocytic hemoglobin value &gt; 2 g/100 mL low limit normal hemoglobin value &lt; 10 g/100 mL ( iv ) Bone lesion : lytic lesion , severe osteopenia , pathologic fracture . Have measurable disease define follow : ( ) Serum Mprotein ≥1g/dL urine Mprotein ≥200 mg/24 hour protein electrophoresis ( ii ) If neither serum urine Mprotein meet criterion , kappa lambda serum FLC must ≥10 mg/dL accompany abnormal kappa lambda ratio ( &lt; 0.26 &gt; 1.65 ) ( Serum FLC use patient without measurable serum urine Mprotein spike . ) Have relapse refractory disease two prior multiple myeloma treatment regimen , may consist either single multiple therapy Be least 3 week beyond last multiple myeloma therapy recover acute toxicity prior therapy measure CTCAE Ver 3.0 . Have Eastern Cooperative Oncology Group performance status 0 2 Have life expectancy least 3 month Be ≥18 year age willing provide write informed consent For woman childbearing potential , must use effective contraceptive method previous 4 week agree continue use method study least 4 month complete study , must include use male/female latex barrier method contraception ( male participant ( See APPENDIX K ) . TMTB pregnancy category D drug . A female childbearing potential define female natural menopause previous , consecutive 24 month , undergone hysterectomy bilateral oophortectomy . Women childbearing potential must negative serum pregnancy test within 24 hour initiation TMTB therapy . Have absolute neutrophil count &gt; 1,000/mm3 Have platelet count &gt; 50,000/mm3 Have total direct bilirubin &lt; 2.0 mg/dL Have aspartate aminotransferase alanine aminotransferase ≤3 time upper limit normal Have serum creatinine ≤2.5 time upper limit normal Have hemoglobin ≥8.5 g/dL All prior treatment related toxicity must CTCAE ( Version 3.0 ) ≤ Grade 1 ( except alopecia ) Subject able swallow retain orally administer medication clinically significant gastrointestinal abnormality may alter absorption malabsorption syndrome major resection stomach bowel Have active infection serious comorbid medical condition Be receive concurrent anticancer agent therapy Be receive concurrent investigational therapy receive investigational therapy within 3 week screen , inclusive molecular genetic testing Be eligible receive standard therapy available know extend life expectancy For woman pregnant , nursing , unwilling unable utilize two form birth control , include use latex condom . Have history another malignancy , except noted Exception : Subjects diseasefree 3 year , subject history completely resect nonmelanoma skin cancer and/or subject indolent second malignancy eligible . Any serious and/or unstable preexist medical disorder ( aside malignancy exception ) , psychiatric disorder , condition could interfere subject 's safety , obtain informed consent compliance study procedure . History interstitial lung disease pneumonitis . Have know immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate study drug , excipients dimethyl sulfoxide ( DMSO ) . Any major surgery , extensive radiotherapy , chemotherapy delay toxicity , biologic therapy , immunotherapy within 21 day prior randomization and/or daily weekly chemotherapy without potential delayed toxicity within 14 day prior randomization . History retinal vein occlusion ( RVO ) Symptomatic untreated spinal cord compression . Known Human Immunodeficiency Virus ( HIV ) , Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV ) infection ( subject laboratory evidence clear HBV HCV infection permit ) . History evidence cardiovascular risk include follow ( See APPENDIX M detail ) : LVEF &lt; LLN b A QT interval ≥ 480 msec correct heart rate use Bazett 's formula ( QTcB ; ) . c History evidence current clinically significant uncontrolled arrhythmia . Exception : Subjects control atrial fibrillation &gt; 30 day prior study enrollment History acute coronary syndrome ( include myocardial infarction unstable angina ) , coronary angioplasty , stenting within 6 month prior study enrollment * History evidence current ≥ Class II congestive heart failure define New York Heart Association ( NYHA ) . Treatment refractory hypertension define blood pressure systolic &gt; 140 mmHg and/or diastolic &gt; 90 mm Hg control antihypertensive therapy ; b Patients intracardiac defibrillator ; c Known cardiac metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>TMTB</keyword>
	<keyword>Mekinist</keyword>
	<keyword>Trametinib</keyword>
	<keyword>relapse</keyword>
	<keyword>refractory</keyword>
	<keyword>response rate</keyword>
</DOC>